Serina Therapeutics (SER) EBT Margin (2018 - 2025)
Serina Therapeutics' (SER) quarterly EBT Margin came in at 4287.69% in Q2 2025, up 389466.0% year-over-year from N/an in Q2 2024, and down 110.78% quarter-over-quarter from 39757.14% in Q4 2024.
Powered by 
Analysis
Serina Therapeutics (SER) EBT Margin (2018 - 2025) Analysis & Trends
Serina Therapeutics has disclosed EBT Margin across 8 years of filings, most recently posting 4287.69% for Q2 2025.
- In Q2 2025, EBT Margin rose 389466.0% year-over-year to 4287.69%; the TTM figure through Jun 2026 stood at 19510.77% (down 233692.0% YoY), while the FY2025 annual figure was 14766.92%, up 524558.0% from the prior year.
- EBT Margin came in at 4287.69% for Q2 2025 at Serina Therapeutics, down from 39757.14% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 39757.14% in Q4 2024 to a low of 54140.0% in Q1 2022.
- Average EBT Margin over 5 years is 15046.94%, with a median of 8164.09% recorded in 2024.
- Year-over-year, EBT Margin slumped 5058107 bps in 2022 and soared 5064667 bps in 2023.
- Over 5 years, EBT Margin stood at 8145.83% in 2021, then plunged by 324 bps to 34500.0% in 2022, then jumped by 100 bps to 2.11% in 2023, then soared by 1888058 bps to 39757.14% in 2024, then slumped by 111 bps to 4287.69% in 2025.
- Per Business Quant data, the three most recent EBT Margin figures were 4287.69% in Q2 2025, 39757.14% in Q4 2024, and 38057.14% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Serina Therapeutics | 40.47 Mn | 17.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -4,287.69% |
| Dec 31, 2024 | 39,757.14% |
| Sep 30, 2024 | -38,057.14% |
| Jun 30, 2024 | -8,182.35% |
| Mar 31, 2024 | -50,140.00% |
| Dec 31, 2023 | 2.11% |
| Sep 30, 2023 | -5,389.66% |
| Jun 30, 2023 | -15,042.86% |
| Mar 31, 2023 | -3,493.33% |
| Dec 31, 2022 | -34,500.00% |
| Sep 30, 2022 | -27,066.67% |
| Jun 30, 2022 | -21,816.67% |
| Mar 31, 2022 | -54,140.00% |
| Sep 30, 2021 | -8,145.83% |
| Jun 30, 2021 | -6,689.19% |
| Mar 31, 2021 | -3,558.93% |
| Dec 31, 2020 | -1,985.44% |
| Sep 30, 2020 | -3,657.97% |
| Jun 30, 2020 | -5,404.44% |
| Mar 31, 2020 | -3,407.87% |